Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026

Bolt Biotherapeutics, Inc.

2026-Q1 EPS reported -$4.31 revenue$26,000

Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.
Cash balance of $23.9M as of March 31, 2026; expected to fund operations into 2027, including dose-escalation completion.
Q1 2026 loss from operations $7.6M vs $12.1M in Q1 2025; R&D expense down to $4.8M from $9.5M.
Two next-generation ISAC programs (CEA and PD-L1) on hold pending BDC-4182 proof-of-concept.
Collaboration revenue fell to $26,000 in Q1 2026 from $1.2M in Q1 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bolt Biotherapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total collaboration revenue was $26,000 for the quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Revenue: Total collaboration revenue was $26,000 for the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

View on SEC.gov

571 earnings releases filed in the last 30 days. Browse all earnings releases →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219361

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.